Patients with oropharyngeal carcinoma who receive proton therapy are more likely to develop this potentially debilitating complication than those who receive IMRT, a new study finds. Medscape Medical News
Patients with oropharyngeal carcinoma who receive proton therapy are more likely to develop this potentially debilitating complication than those who receive IMRT, a new study finds. Medscape Medical News